State of Wyoming Sells 12,771 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

Key Points

• The State of Wyoming sold 12,771 shares of Catalyst Pharmaceuticals, reducing its holdings by 50.2% during the first quarter, leaving it with a total of 12,647 shares worth $307,000.
• Institutional investors own 79.22% of Catalyst Pharmaceuticals' stock, with several firms making recent adjustments to their positions, including Park Square Financial Group and PNC Financial Services Group.
• Analysts have mixed ratings for Catalyst Pharmaceuticals, with Wall Street Zen and Zacks Research downgrading it to "hold," while Cantor Fitzgerald upgraded it to a "strong-buy," indicating varying confidence among market experts.

State of Wyoming lowered its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 50.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,647 shares of the biopharmaceutical company's stock after selling 12,771 shares during the period. State of Wyoming's holdings in Catalyst Pharmaceuticals were worth $307,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in CPRX. Park Square Financial Group LLC bought a new position in Catalyst Pharmaceuticals during the 4th quarter worth $29,000. Sound Income Strategies LLC bought a new position in Catalyst Pharmaceuticals during the 1st quarter worth $64,000. GAMMA Investing LLC increased its stake in Catalyst Pharmaceuticals by 26.2% during the 1st quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock worth $68,000 after acquiring an additional 579 shares during the period. PNC Financial Services Group Inc. increased its stake in Catalyst Pharmaceuticals by 57.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 5,501 shares of the biopharmaceutical company's stock worth $133,000 after acquiring an additional 2,002 shares during the period. Finally, US Bancorp DE increased its stake in Catalyst Pharmaceuticals by 17.8% during the 1st quarter. US Bancorp DE now owns 7,328 shares of the biopharmaceutical company's stock worth $178,000 after acquiring an additional 1,105 shares during the period. Institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX opened at $20.59 on Tuesday. Catalyst Pharmaceuticals, Inc. has a 52-week low of $19.00 and a 52-week high of $26.58. The business's fifty day moving average is $20.99 and its 200-day moving average is $22.49. The firm has a market cap of $2.52 billion, a price-to-earnings ratio of 12.48, a PEG ratio of 0.84 and a beta of 0.85.

Insiders Place Their Bets

In related news, insider Preethi Sundaram sold 2,324 shares of the firm's stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $26.41, for a total transaction of $61,376.84. Following the sale, the insider owned 42,681 shares of the company's stock, valued at $1,127,205.21. This trade represents a 5.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Steve Miller sold 115,000 shares of the firm's stock in a transaction on Tuesday, August 26th. The shares were sold at an average price of $20.28, for a total value of $2,332,200.00. Following the sale, the insider directly owned 949,663 shares in the company, valued at approximately $19,259,165.64. This trade represents a 10.80% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 167,894 shares of company stock worth $3,434,690. 10.40% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have commented on CPRX shares. Wall Street Zen lowered Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Saturday, August 9th. Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, June 5th. Finally, Zacks Research lowered Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, Catalyst Pharmaceuticals presently has an average rating of "Buy" and a consensus price target of $33.20.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.